La Jolla Pharmaceutical Co

La Jolla Pharmaceutical — Technical Presentation (February 2017)

16 slides from La Jolla Pharmaceutical's technical presentation, Feb 28, 2017

  1. Slide 1: ATHOS-3 Phase 3 Study of LJPC-501 Positive Topline Results

    ATHOS-3 Phase 3 Study of LJPC-501 Positive Topline Results February 27, 2017

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement These slides contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the company’s future results of operations. These statements are only predictions or statements of cu

  3. Slide 3: Mission Statement

    Mission Statement La Jolla is dedicated to improving the lives of patients suffering from life-threatening diseases by discovering and developing innovative therapies

  4. Slide 4: Catecholamine Resistant Hypotension (CRH) Remains a Major Unmet Medical Need

    Catecholamine Resistant Hypotension (CRH) Remains a Major Unmet Medical Need

  5. Slide 5: Shock: Deadly, Costly and Prevalent

    Shock MORTALITY RATES COMPARED Shock: Deadly, Costly and Prevalent 1. Vincent JL, De Backer D. N Engl J Med. 2013;369(18):1726-1734. 2. Sviri S, Hashoul J, Stav I, van Heerden PV. J Crit Care. 2014;29(1):157-160. 3. Readmissions and deaths-national. Data.Medicare.gov website. https://data.medicare.g

  6. Slide 6: CMS Covered Charges for CRH Population Are Much Greater Than for Other Acute Hospital Conditions

    CMS Covered Charges for CRH Population Are Much Greater Than for Other Acute Hospital Conditions 6 Source: CMS FY14 Inpatient Public Use File (IPUF) $87,282 $42,243 $31,453 $30,702 CRH AMI CHF Pneumonia Weighted Average CMS Covered Charges Abbreviations: AMI=acute myocardial infarction; CHF=congesti

  7. Slide 7: U.S. Shock Patient Population and Treatment Paradigm

    U.S. Shock Patient Population and Treatment Paradigm 7 1. 9.42MM annualized vials (785K vials sold in January 2017 X 12); Symphony Health Solutions, 2017. 97% of vials sold for hypotensive shock; estimate based on medical literature. 13 vials used per patient; estimate based on Russell et al, N Engl

  8. Slide 8: Randomized Study of Vasopressin VASST Overall Survival

    Randomized Study of Vasopressin 8 VASST Overall Survival1 VASST=Vasopressin and Septic Shock Trial 1. Russell JA, Walley KR, Singer J, et al. for VASST Investigators. N Engl J Med. 2008;358(9):877-887 Day 28 HR=0.90 (95%CI: 0.75-1.08) P=0.27 Day 90 HR=0.88 (95%CI: 0.76-1.03) P=0.10

  9. Slide 9: LJPC-501: The First Synthetic Human Angiotensin II Tested in a Randomized Phase 3 Study

    LJPC-501: The First Synthetic Human Angiotensin II Tested in a Randomized Phase 3 Study

  10. Slide 10: LJPC-501: The First Synthetic Human Angiotensin II Tested in a Randomized Phase 3 Study

    LJPC-501: The First Synthetic Human Angiotensin II Tested in a Randomized Phase 3 Study 10 • LJPC-501 is a proprietary formulation of synthetic human angiotensin II, a naturally occurring regulator of blood pressure • Angiotensin II has been shown to raise blood pressure in a pilot, randomized, plac

  11. Slide 11: Three Systems Work in Harmony to Regulate Blood Pressure

    Three Systems Work in Harmony to Regulate Blood Pressure Existing Treatments for Shock Only Utilize Two Systems THERAPIES AND ASSOCIATED ADVERSE EVENTS SYMPATHETIC NERVOUS ARGININE- VASOPRESSIN RENIN ANGIOTENSIN- ALDOSTERONE 11 CATECHOLAMINES1: SYMPATHETIC NERVOUS Prolonged elevated heart rate, tach

  12. Slide 12: ATHOS-3 Study Design

    Primary endpoint Percentage of patients achieving pre-specified target blood pressure response1 ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Study Design 12 1. Mean Arterial Pressure (MAP) ≥ 75 mmHg OR a 10 mmHg increase from baseline MAP at 3 hours following the initiation of stu

  13. Slide 13: ATHOS-3 Topline Results: Primary Endpoint

    ATHOS-3 Topline Results: Primary Endpoint Primary Efficacy Endpoint Placebo LJPC-501 P-Value Percentage of patients achieving pre-specified target blood pressure response1 23% 70% <0.00001 13 1. Mean Arterial Pressure (MAP) ≥ 75 mmHg OR a 10 mmHg increase from baseline MAP at 3 hours following the i

  14. Slide 14: ATHOS-3 Topline Results: Mortality

    ATHOS-3 Topline Results: Mortality Estimated Risk Reduction Hazard Ratio 1 95% Confidence Interval P-Value 22% 0.78 0.57-1.07 0.12 1. Proportional hazards estimate (unadjusted) of mortality to Day 28 comparing placebo-treated patients to LJPC-501-treated patients 14 • Trend toward longer survival ob

  15. Slide 15: ATHOS-3 Topline Results: Safety

    ATHOS-3 Topline Results: Safety Placebo LJPC-501 Percentage of patients experiencing at least one adverse event 92% 87% Percentage of patients discontinuing treatment due to an adverse event 22% 14% 15 • Throughout the study, safety outcomes were followed by an independent Data Safety Monitoring Boa

  16. Slide 16: Thank You

    We plan to present and publish detailed results from ATHOS-3 later this year Thank You

LA Jolla Pharmaceutical — Technical Presentation (February 2017) on 6ix